TROP-2

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. ... Read more

February 16, 2017

Seattle Genetics and Immunomedics to Develop IMMU-132 for Triple Negative Breast Cancer, Other Solid Tumors

News

Seattle Genetics and Immunomedics are collaborating to develop and market IMMU-132, currently being studied for the treatment of triple negative breast cancer and other solid tumors. Under the terms of the licensing agreement, ... Read more

January 9, 2015January 9, 2015

Drug For Triple-Negative Breast Cancer Treatment Received Fast Track Designation By FDA

News

Immunomedics, Inc. has announced its sacituzumab govitecan research received the U.S. Food and Drug Administration (FDA) designation of Fast Track development program for the treatment of triple negative breast cancer ... Read more